Tailored Antiplatelet Therapy Following PCI
Public ClinicalTrials.gov record NCT01742117. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Tailored Antiplatelet Initiation to Lesson Outcomes Due to Decreased Clopidogrel Response After Percutaneous Coronary Intervention (TAILOR-PCI)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Clopidogrel is an anti-platelet medication approved by the U.S. Federal Drug Administration (FDA) for use in patients who undergo Percutaneous Coronary Intervention (PCI) with coronary stent implantation. Anti-platelet medications work to prevent blood clots from forming. Some studies have suggested that patients who have a certain genetic liver enzyme abnormality (known as cytochrome P450 2C19 \[CYP2C19\] \*2 or \*3 allele) may have a reduced ability to activate clopidogrel, and therefore may have a lowered response to clopidogrel. It is thought that perhaps people who have a coronary stent procedure may have this genetic liver enzyme abnormality. There is a research genetic test available to determine whether or not someone has this genetic liver enzyme abnormality. Ticagrelor, is a newer anti-platelet drug that is not dependent on the CYP2C19 liver enzyme for its activation and hence in poor clopidogrel metabolizers, alternative drugs like Ticagrelor have been recommended for use as an anti-platelet agent after PCI. The purpose of this study is to determine if genetic testing can identify the best anti-platelet therapy, for patients who undergo a coronary stent placement and do not activate clopidogrel very well.
Study identification
- NCT ID
- NCT01742117
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 5,276 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2013 (Type not available)
- Primary completion
- Oct 31, 2020 (Actual)
- Completion
- Oct 31, 2020 (Actual)
- Last update posted
- Nov 9, 2021
2013 – 2020
United States locations
- U.S. sites
- 26
- U.S. states
- 12
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic in Arizona | Scottsdale | Arizona | 85259 | — |
| Sharp HealthCare | San Diego | California | 92123 | — |
| Zuckerberg San Francisco General | San Francisco | California | 94110 | — |
| Mayo Clinic in Florida | Jacksonville | Florida | 32224 | — |
| NCH Heart Institute | Naples | Florida | 34102 | — |
| NorthShore University Health System | Evanston | Illinois | 60201 | — |
| Loyola University Medical Center | Maywood | Illinois | 60153 | — |
| St. Elizabeth Healthcare | Crestview Hills | Kentucky | 41017 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| Essentia Institute of Rural Health | Duluth | Minnesota | 55805 | — |
| Minneapolis Heart Institute | Minneapolis | Minnesota | 55407 | — |
| University of Minnesota | Minneapolis | Minnesota | 55455 | — |
| Mayo Clinic in Rochester | Rochester | Minnesota | 55905 | — |
| The University of Mississippi Medical Center | Jackson | Mississippi | 39216 | — |
| Albany Medical College | Albany | New York | 12208 | — |
| The Feinstein Institute for Medical Research | Manhasset | New York | 11030 | — |
| Winthrop University Hospital | Mineola | New York | 11501 | — |
| New York University Langone Medical Center | New York | New York | 10016 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| Cardiology Associates of Schenectady | Schenectady | New York | 12309 | — |
| Rhode Island Hospital | Providence | Rhode Island | 02903 | — |
| The Miriam Hospital | Providence | Rhode Island | 02906 | — |
| Greenville Health System | Greenville | South Carolina | 29605 | — |
| MHS, Eau Claire | Eau Claire | Wisconsin | 54702 | — |
| Mayo Clinic Health System | La Crosse | Wisconsin | 54601 | — |
| Aurora Health Care | Milwaukee | Wisconsin | 53215 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01742117, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 9, 2021 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01742117 live on ClinicalTrials.gov.